Zogenix, Inc., a pharmaceutical company, develops and commercializes therapies for the treatment of central nervous system disorders in the United States. Its lead product candidate is the ZX008, a low-dose fenfluramine, which is in Phase III clinical trials for the treatment of seizures associated with Dravet syndrome. The company was formerly known as SJ2 Therapeutics, Inc. and changed its name to Zogenix, Inc. in August 2006. Zogenix, Inc. was founded in 2006 and is headquartered in Emeryville, California.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryPharmaceuticals
SectorMedical
Current SymbolNASDAQ:ZGNX
Previous Symbol
CUSIP98978L10
Phone510-550-8300
Debt
Debt-to-Equity RatioN/A
Current Ratio9.89
Quick Ratio9.89
Price-To-Earnings
Trailing P/E Ratio-10.13
Forward P/E Ratio-10.84
P/E GrowthN/A
Sales & Book Value
Annual Sales$9.82 million
Price / Sales174.12
Cash FlowN/A
Price / CashN/A
Book Value$12.84 per share
Price / Book3.17
Profitability
EPS (Most Recent Fiscal Year)($4.02)
Net Income$-126,810,000.00
Net MarginsN/A
Return on Equity-38.56%
Return on Assets-28.83%
Miscellaneous
Employees68
Outstanding Shares41,970,000
Market Cap$1.71 billion
OptionableOptionable
Zogenix (NASDAQ:ZGNX) Frequently Asked Questions
What is Zogenix's stock symbol?
Zogenix trades on the NASDAQ under the ticker symbol "ZGNX."
How were Zogenix's earnings last quarter?
Zogenix, Inc. (NASDAQ:ZGNX) posted its quarterly earnings data on Thursday, November, 8th. The company reported ($1.08) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.88) by $0.20. During the same quarter last year, the company posted ($1.68) EPS. View Zogenix's Earnings History.
When is Zogenix's next earnings date?
What price target have analysts set for ZGNX?
10 brokers have issued 12-month price objectives for Zogenix's stock. Their forecasts range from $56.00 to $116.00. On average, they expect Zogenix's stock price to reach $71.1111 in the next twelve months. This suggests a possible upside of 74.5% from the stock's current price. View Analyst Price Targets for Zogenix.
What is the consensus analysts' recommendation for Zogenix?
10 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Zogenix in the last year. There are currently 10 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Zogenix.
What are Wall Street analysts saying about Zogenix stock?
Here are some recent quotes from research analysts about Zogenix stock:
- 1. According to Zacks Investment Research, "Zogenix, Inc. is a pharmaceutical company engaged in the development and commercialization of treatment products for central nervous system disorders and pain. Its first commercial product, Sumavel DosePro is a needle-free Delivery System used in the treatment of acute migraine and cluster headache in a pre-filled, single-use delivery system. Its lead product candidate, ZX002, is a novel, oral and single-entity controlled-release formulation of hydrocodone used for the treatment of moderate to severe chronic pain in patients requiring around-the-clock opioid therapy. Zogenix, Inc. is headquartered in San Diego, CA. " (11/17/2018)
- 2. Mizuho analysts commented, "We see the recent share weakness post-study 1504 readouts as a buying opportunity. We believe upside potential remains from the LGS indication in 2019 and we believe Zogenix is in comfortable position to reach break-even following a recent $359 mil capital raise. In addition, we see the FDA approval of stiripentol on 08/21/18 as incrementally positive for ZX008 from an IP protection perspective. The known drug-drug interaction (DDI) of ZX008 with stiripentol is protected by Zogenix patents and is likely to create an extra hurdle for potential generic competitors down the road." (8/24/2018)
Has Zogenix been receiving favorable news coverage?
Media coverage about ZGNX stock has been trending neutral recently, InfoTrie reports. The research firm identifies negative and positive media coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. Zogenix earned a news impact score of 0.2 on InfoTrie's scale. They also gave press coverage about the company a news buzz of 9.0 out of 10, indicating that recent media coverage is extremely likely to have an impact on the stock's share price in the near term.
Who are some of Zogenix's key competitors?
Some companies that are related to Zogenix include Beigene (BGNE), Nektar Therapeutics (NKTR), Dr.Reddy's Laboratories (RDY), Catalent (CTLT), Amneal Pharmaceuticals (AMRX), GALAPAGOS NV/S (GLPG), Alkermes (ALKS), SAGE Therapeutics (SAGE), Amarin (AMRN), United Therapeutics (UTHR), Loxo Oncology (LOXO), Agios Pharmaceuticals (AGIO), HUTCHISON CHINA/S (HCM), GW Pharmaceuticals PLC- (GWPH) and Taro Pharmaceutical Industries (TARO).
Who are Zogenix's key executives?
Zogenix's management team includes the folowing people:
- Dr. Stephen J. Farr, Co-Founder, CEO, Pres & Director (Age 59)
- Mr. Roger L. Hawley B.S., Co-Founder & Director (Age 65)
- Mr. Michael P. Smith, Exec. VP, CFO, Treasurer & Sec. (Age 50)
- Dr. Bradley S. Galer, Exec. VP & Chief Medical Officer (Age 56)
- Dr. Gail M. Farfel, Exec. VP & Chief Devel. Officer (Age 54)
Who are Zogenix's major shareholders?
Zogenix's stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include Scopia Capital Management LP (14.81%), Perceptive Advisors LLC (10.63%), BlackRock Inc. (10.06%), Bank of New York Mellon Corp (7.11%), FMR LLC (3.59%) and Eagle Asset Management Inc. (2.66%). Company insiders that own Zogenix stock include Bradley S Galer, Cam L Garner, Gail M Farfel, Life Sciences Maste Perceptive, Renee P Tannenbaum and Roger Hawley. View Institutional Ownership Trends for Zogenix.
Which institutional investors are selling Zogenix stock?
ZGNX stock was sold by a variety of institutional investors in the last quarter, including Perceptive Advisors LLC, Franklin Resources Inc., Artal Group S.A., Alliancebernstein L.P., Dimensional Fund Advisors LP, Eagle Asset Management Inc., Credit Suisse AG and EAM Investors LLC. Company insiders that have sold Zogenix company stock in the last year include Cam L Garner, Gail M Farfel and Roger Hawley. View Insider Buying and Selling for Zogenix.
Which institutional investors are buying Zogenix stock?
ZGNX stock was bought by a variety of institutional investors in the last quarter, including Scopia Capital Management LP, Bank of New York Mellon Corp, BlackRock Inc., Emerald Advisers Inc. PA, Emerald Mutual Fund Advisers Trust, Loomis Sayles & Co. L P, Bailard Inc. and Tavio Capital LLC. Company insiders that have bought Zogenix stock in the last two years include Bradley S Galer, Life Sciences Maste Perceptive and Renee P Tannenbaum. View Insider Buying and Selling for Zogenix.
How do I buy shares of Zogenix?
Shares of ZGNX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Zogenix's stock price today?
One share of ZGNX stock can currently be purchased for approximately $40.74.
How big of a company is Zogenix?
Zogenix has a market capitalization of $1.71 billion and generates $9.82 million in revenue each year. The company earns $-126,810,000.00 in net income (profit) each year or ($4.02) on an earnings per share basis. Zogenix employs 68 workers across the globe.
What is Zogenix's official website?
How can I contact Zogenix?
Zogenix's mailing address is 5858 Horton Street Suite 455, EMERYVILLE CA, 94608. The company can be reached via phone at 510-550-8300 or via email at [email protected]
MarketBeat Community Rating for Zogenix (NASDAQ ZGNX)
MarketBeat's community ratings are surveys of what our community members think about Zogenix and other stocks. Vote "Outperform" if you believe ZGNX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ZGNX will underperform the S&P 500 over the long term. You may vote once every thirty days.
